Moreover, while MCL treatment assuaged the effects of BRG1-induced-ECM deposition and TGF-β1-Smad3 signaling, the mutation of BRG1 N1540A prevented any further effects of MCL (Fig. 7h, i, Additional file 1: Fig. S4b–g). This evidence concerns the gene SMARCA4 and mantle cell lymphoma.